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Background: Oral immunization with vaccines may be an effective strategy for prevention of Clostridium difficile
infection (CDI). However, application of previously developed vaccines for preventing CDI has been limited due
to various reasons. Here, we developed a recombinant Lactococcus lactis oral vaccine and evaluated its effect on
a C. difficile-infected animal model established in golden hamsters in attempt to provide an alternative strategy
for CDI prevention.
Methods: Recombinant L. lactis vaccine was developed using the pTRKH2 plasmid, a high-copy-number
Escherichia coli-L. shuttle vector: 1) L. lactis expressing secreted proteins was constructed with recombinant
pTRKH2 (secreted-protein plasmid) carrying the Usp45 signal peptide (SPUsp45), nontoxic adjuvanted tetanus
toxin fragment C (TETC), and 14 of the 38 C-terminal repeats (14CDTA) of nontoxic C. difficile toxin A (TcdA); and
2) L. lactis expressing secreted and membrane proteins was constructed with recombinant pTRKH2 (membrane-anchored
plasmid) carrying SPUsp45, TETC, 14CDTA, and the cell wall-anchored sequence of protein M6 (cwaM6). Then, 32 male
Syrian golden hamsters were randomly divided into 4 groups (n = 8 each) for gavage of normal saline (blank control) and
L. lactis carrying the empty shuttle vector, secreted-protein plasmid, and membrane-anchored plasmid, respectively. After
1-week gavage of clindamycin, the animals were administered with C. difficile spore suspension. General symptoms and
intestinal pathological changes of the animals were examined by naked eye and microscopy, respectively. Protein levels
of anti-TcdA IgG/IgA antibodies in intestinal tissue and fluid were analyzed by enzyme-linked immunosorbent assay
(ELISA). A cell culture cytotoxicity neutralization assay was done by TcdA treatment with or without anti-TcdA serum
pre-incubation or treatment. Apoptosis of intestinal epithelial cells was examined by flow cytometry (FL) assay.
Expression of mucosal inflammatory cytokines in the animals was detected by polymer chain reaction (PCR) assay.
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Results: After the C. difficile challenge, the animals of control group had severe diarrhea symptoms on day 1 and all
died on day 4, indicating that the CDI animal model was established in hamster. Of the 3 immunization groups,
secreted-protein and membrane-anchored plasmid groups had significantly lower mortalities, body weight decreases,
and pathological scores, with higher survival rate/time than the empty plasmid group (P < 0.05). The tilter of IgG
antibody directed against TcdA was significantly higher in serum and intestinal fluid of secreted-protein and
membrane-anchored plasmid groups than in the empty plasmid group (P < 0.05) while the corresponding titer of IgA
antibody directed against TcdA had no substantial differences (P > 0.05). The anti-TcdA serum of membrane-anchored
plasmid group neutralized the cytotoxicity of 200 ng/ml TcdA with the best protective effect achieved by anti-TcdA
serum pre-incubation. The incidences of TcdA-induced death and apoptosis of intestinal epithelial cells were
significantly reduced by cell pre-incubation or treatment with anti-TcdA serum of membrane-anchored plasmid
group (P < 0.05). MCP-1, ICAM-1, IL-6, and Gro-1 mRNA expression levels were the lowest in cecum tissue of the
membrane-anchored groups compared to the other groups.
Conclusion: Recombinant L. lactis live vaccine is effective for preventing CDI in the hamster model, thus providing
an alternative for immunization of C. difficile-associated diseases.
Keywords: Clostridium difficile, Recombinant Lactococcus lactis, Secreted-protein plasmid, Membrane-anchored
plasmid, Golden hamstersBackground
Clostridium difficile is one of the most important patho-
gens in nosocomial infections. C. difficile infection (CDI)
causes 10–20% of antibiotic-associated diarrhea, 75% of
antibiotic-associated colitis, and nearly 100% of pseudo-
membranous colitis in hospitals (referred to as C. difficile-
associated diseases, CDADs), leading to billions of dollars
in economic losses worldwide every year [1]. In general,
CDADs occur mainly in people with long-term use of
antibiotics, the use of anticancer drugs, long-term hospi-
talization or immune defects, especially those with a decline
in immune function or the elderly [1]. With the develop-
ment of medical industry and the increasing use of antibi-
otics, the rate of CDI has been substantially increased in
China [2]. Effective strategies are urgently needed for CDI
prevention in the high-risk population of CDADs.
Due to antibiotic resistance and inherent physiological
factors of the pathogen, antibiotic treatment of CDI can
be challenging while oral immunization with vaccines is
generally considered to be an important pathway for CDI
prevention [1]. Vaccine development involves the establish-
ment of an appropriate animal model and further evalu-
ation of the efficacy and safety of the vaccine. In previous
research of C. difficile vaccines, Kink et al. [3] successfully
established CDI model in hamster by intragastric gavage
of 105CFU C. difficile 18–24 h after subcutaneous injec-
tion of clindamycin (CLDM, 1 mg per 100 g body weight),
and Torres et al. [4] administered the animals with 105CFU
C. difficile 3-h after CLDM gavage (0.5 mg per 100 g body
weight). In general, golden hamster is considered ideal for
establishing CDI model, because C. difficile-produced toxins
can be neutralized by anti-C. difficile antibodies and CLDM-induced colitis model can be used as animal model of
human CDIs.
Regarding the development of vaccines for C. difficile,
great research progress has been made over the last two
decades [1]. For example, Torres et al. [4] reported that
formalin-inactivated C. difficile culture filtrate has a pro-
tective effect on hamsters by nasal, peritoneal, or subcuta-
neous administration. Ryan et al. [5] and Ward et al. [6]
developed recombinant vaccines for C. difficile by engin-
eering a plasmid to express recombinant toxin A proteins
from the nontoxic C-terminal receptor binding region of
C. difficile toxin A (TcdA) covalently bonded to polysaccha-
ride of other bacterium, and then introducing this plasmid
into attenuated Salmonella typhimuriu or Vibrio cholerae.
However, the application of previously developed vaccines
for C. difficile has been limited for various reasons:
1) Vaccines for passive immunization of CDI are thought
expensive and inconvenient in storage and transport;
2) Attenuated vaccines are commonly treated with forma-
lin to inactivate the antigen or given with adjuvant, some-
times through invasive routes of immunization such as
subcutaneous and intraperitoneal injection, thus are not
easily accepted by the patients. 3) Recombinant vaccines
that are carried by attenuated S. typhimuriu or V. cholerae
are of concern in terms of biosafety [1].
Lactococcus lactis is a harmless food industry bacterium
that has been used extensively for producing a variety of
peptides, proteins, and oral vaccines. As compared to the
vaccine carrier E. coli, L. lactis can be a superior alterna-
tive because it produces less protease with no endotoxin
[7]. In the literature, Dieye et al. [8] designed a protein-
targeting system for lactic acid bacteria and found that the
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moter and Usp45 single peptide (SPUsp45) was capable of
expression and extracellular secretion of target nuclease
while the expression system constructed with P59, Usp45,
and the cell wall-anchored sequence of protein M6
(cwaM6) was capable of extracellular secretion of the
nuclease as well as anchoring it onto the cell wall of
L. lactis and Bacterium lacticum. In a following study,
Ribeiro et al. [9] expressed a fusion protein containing
the Brucella abortus antigen L7/L12 and the Streptococcus
pyogenes cwaM6 in L. lactis, which allowed the antigen
anchored on the cell surface, thus improving its antigenic-
ity. These authors further developed a food-grade live
vaccine for immunization of B. abortus, which showed a
protective effect on mice under laboratory conditions
[9]. In addition, Mannam et al. [10] made a mucosal vac-
cine from live, recombinant L. lactis, which protected
mice against pharyngeal infection with S. pyogenes. To-
gether these researches have provided a completely new
direction for development of vaccines, especially live pro-
biotic preparations for oral immunization.
Despite potential advantages of L. lactis as the carrier
of live vaccine, no studies have been reported on oral
immunization with L. lactis live vaccines for preventing
CDI till date. Whether vaccines made from live, recom-
binant L. lactis are effective for preventing CDI remains
unclear. Previously, we constructed a gene expression
system in L. lactis based on the work by Dieye et al. [8].
In the present study, we modified the gene expression
system to develop recombinant L. lactis live vaccine for
C. difficile, and then vaccinated a CDI animal model of
golden hamsters by oral immunization. Pathological and
immunological parameters of the animals were assayed
under laboratory conditions. Results were used to evalu-
ate the effect of recombinant L. lactis live vaccine for
preventing CDI.
Methods
Plasmid, C. difficile culture, cell lines
The pTRKH2 plasmid [11], a high-copy-number E. coli-
L. lactis shuttle vector, was kindly provided by Klanenhammer
TR (Department of Food Science, North Carolina State
University). C. difficile VPI10463 was purchased from
Lanzhou Institute of Biological Products (Lanzhou, China).
The pathogen was cultured in Brain-Heart Infusion medium
(BHI) (Difco) containing 5 mg/ml yeast extract and 0.1%
L-cysteine at 37°C for 72 h in an anaerobic chamber (Coy
Laboratory Products). CHO-K1 and T84 cells were pur-
chased from the Institute of Basic Medical Sciences, Chinese
Academy of Medical Sciences (Beijing, China). The two cell
lines were respectively cultured in F12 and DMEM-F12
media (Gibco) containing 10% heat-inactivated fetal bovine
serum, 100 U/ml penicillin, and 100 μg/ml streptomycin at
37°C in a CO2 incubator (5% CO2, saturated humidity).Preparation of recombinant L. lactis live vaccine and
C. difficile spore suspension
Recombinant L. lactis live vaccine was prepared using
the shuttle vector pTRKH2 as previously reported by
Yang et al. [12,13]. A slight modification was that the
nontoxic tetanus toxin fragment C (TETC) was inserted
to the L. lactis expression system as a biological adju-
vant. That is, L. lactis expressing secreted proteins was
constructed with recombinant pTRKH2 (secreted-protein
plasmid) carrying the secretory signal peptide SPUsp45,
nontoxic adjuvanted TETC, and 14 of the 38 C-terminal
repeats (14CDTA) of TcdA; and L. lactis expressing
secreted and membrane proteins was constructed with
recombinant pTRKH2 (membrane-anchored plasmid)
carrying SPUsp45, TETC, 14CDTA, and the cell wall-
anchored sequence cwaM6. L. lactis cell suspension
(5 × 109CFU/ml) was prepared in 0.2M sodium bicarbon-
ate containing 5% casein hydrolyzate and 0.5% glucose.
C. difficile was induced on BHIS agar as described
previously [14]. Briefly, the overnight culture broth of
C. difficile in BHIS medium was diluted in fresh BHIS
medium to an optical density (OD, 600 nm) of 0.2. Then,
150 ml of diluted culture suspension was spread on 5 ml
of BHIS agar dispensed in each well of a 6-well tissue
culture dish, followed by anaerobic incubation at 37°C
for 4–7 d. To examine the colony formation from
C. difficile spores, samples were taken from the plates
containing a mixture of spores and vegetative cells and
then resuspended in BHIS medium. The suspension was
heated to 60°C for 20 min to kill vegetative cells and then
cooled, diluted and plated onto BHIS medium. For use in
germination assays, C. difficile spores were purified using
the method of Akoachere et al. [15] withminor modifi-
cations. The spore-vegetative cell mixture was harvested
by flooding each well of the 6-well dish with ice-cold
sterile water. After 5 washes with ice-cold water, the
mixture of spores and vegetative cells were resuspended
in 20%w/v HistoDenz (Sigma, St. Louis, MO, USA), lay-
ered onto a 50%w/v HistoDenz solution in a centrifuge
tube, and then centrifuged at 15,0007× g for 15 min to
separate spores from vegetative cells. The purified spores,
collected at the bottom of the centrifuge tube, were washed
twice with ice-cold water to remove traces of HistoDenz
and then resuspended in distilled water.
Animal experiment
Oral immunization with L. lactis vaccine
Thirty-two male Syrian golden hamsters with a weight
of 100–130 g were purchased from the Slac Laboratory
Animal Co., Ltd. (Shanghai, China). The golden hamsters
were randomly divided into 4 groups (n = 8 each) for gastric
perfusion of 1 ml suspension of normal saline (control) and
L. lactis carrying the empty shuttle vector, secreted-protein
plasmid, and membrane-anchored plasmid, respectively (on
Figure 1 Schematic diagram of Clostridium difficile challenge
experiment.
Yang et al. BMC Gastroenterology 2013, 13:117 Page 4 of 13
http://www.biomedcentral.com/1471-230X/13/117days 0, 1, 2, 7, 14, and 23). Intestinal flora in the animals
was examined on days 7 and 14 prior to gastric perfusion.
Mortality, diarrhea incidence, weight change from before
to after the challenge, and survival time of the animals
were examined and determined for evaluating the effect of
recombinant L. lactis vaccine on the CDI animals model.
The animal experiment was approved by the Ethics com-
mittee of General Hospital of Guangzhou Military Com-
mand of People’s Liberation Army.
C. difficile challenge experiment
From day 15, 10 g of CLDM (clindamycin hydrochloride,
North China Pharmaceutical Co., Ltd, Shijiazhuang, China)
was administered to the animals by gavage once daily
for one week. Then, intestinal flora of the animals was
analyzed, and C. difficile was cultured and isolated to
determine potential imbalance in the intestinal flora
and the incidence of CDI. Each animal was weighed
and then exposed to 4 × 105CFU C. difficile 4 h after the
last administration of CLDM on day 21. The animals were
observed every 4 h for 72 h. Feces samples were taken for
cultivation and isolation of C. difficile and L. lactis. There-
after, the animals were observed 4 times a day on the
feces, perianal area, activity, fur morphology, and gloss
and mental status. The animals were scored based on the
observations as follows [3,4]: 0, normal; 1, light stool, nor-
mal activity; 2, wet perianal and tail, close to normal acti-
vity; 3, less activity but respond to stimuli; soft abdomen;
and 4, wet tail, claws and lower abdomen; curled; no acti-
vity; soft abdomen; balance impaired; fur shrug. Animals
were killed when the score was 4, and the surviving
animals were sacrificed at the end of the experiment
on day 35, i.e., 14 days after Clostridium exposure
(Figure 1).
Serum, intestinal tissue, and intestinal fluid
specimen preparation
The animals were treated with ether for mild anesthesia
before sacrificed. Skin infection was done with alcohol.
The thoracic cavity was cut and opened with scissors.
Blood was taken from the heart through a fine needle and
then centrifuged at 13000 g, 4°C for 15 min. The super-
natant serum was collected and stored at −70°C prior to
serum enzyme-linked immunosorbent assay (ELISA). For
preparation of intestinal specimens, the intestinal tract
was taken from the animals, with surrounding blood ves-
sels and adipose tissues carefully removed. The remaining
material was washed with pre-cooled phosphate-buffered
saline (PBS). Then, 100 mg of intestinal tissue was weighed
into a 1.5-ml microcentrifuge tube containing 0.5 ml of TE
buffer with the proteinase inhibitor Cocktail (Roche, USA).
Protein components were extracted by homogenization
and subsequent centrifugation (13000 g, 4°C, 15 min), with
the supernatant collected and stored at −70°C prior to use.Finally, 100 mg of ileum to colon tissue was weighted into
a 1.5-ml microcentrifuge containing 0.5 ml of PBS buffer
with trypsin inhibitor. The ileum to colon tissue was cut
into pieces and moderately stirred for 30 min, then incu-
bated at 4°C for 10 h. After centrifugation (13000 g, 4°C for
15 min), the supernatant (intestinal mucus) was collected
and stored at −70°C prior to use.
Pathological analysis and scoring
The animals of different treatments were dissected, with
abdominal and intestinal lesions examined by naked eye.
Part of the cecum and colon tissues was taken and cut
along the longitudinal axis. After the intestinal contents
were washed with 4°C normal saline, 100 mg of intestinal
mucosal tissue was weighed and immediately homoge-
nized for cultivation and isolation of C difficile and
L. lactis. Intestinal total RNA and total protein, cytoplas-
mic protein and nuclear protein of intestinal epithelial
cells were extracted from 200 mg of intestinal mucosal tis-
sue. Pathological changes in the intestine were observed
under a stereoscope and a dissecting microscope (Olympus
SZX7, Tokyo, Japan). Then, the tissues were fixed in 10%
neutral formalin, embedded in paraffin, HE-stained, and
observed under a light microscope (Olympus BX40, Tokyo,
Japan). The criteria for the macropathological score and
histopathological score are shown in Tables 1 and 2,
respectively.
Evaluation index system and statistical analyses
The effect of recombinant L. lactis on C. difficile-
infected animals was evaluated using the following indices:
mortality, diarrhea incidence, weight changes from before
to after C. difficile challenge, and survival time of the
infected animals. Mortality and diarrhea incidence data
were analyzed by Pearson’s chi-square test. P ≤ 0.05 was
considered statistically significant. Weight change and
pathological score data were as the mean ± standard





Local congestion, edema, non-erosive 1
1-2 erosion Additional 1–2 points
>2 erosions Additional 3 points
One ulcer Additional 4 points
>2 ulcers Additional 5 points
Complicated with hemorrhage Additional 1–3 points
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The variance nonhomogeneity was tested by rank sum
test, and P ≤ 0.05 considered statistically significant. Sur-
vival time data were analyzed using the Kaplan-Meier



























The tilters of anti-C. difficile toxin A (TcdA) antibodies
in serum, intestinal tissue, and intestinal fluid specimens
were determined using an anti-TcdA hamster IgG/IgA
ELISA test kit (Adlitteram Diagnostic Laboratories) follow-
ing the manufacturer’s instructions. Results were compared
among different treatments using single-factor analysis of
variance (ANOVA). Data were checked for normal distri-
bution prior to statistical analysis and log-transformed
when necessary.
Cell culture cytotoxicity neutralization assay
The antagonism of anti-TcdA antibodies produced in
hamster serum of the membrane-anchored plasmid group
was evaluated by a cell culture cytotoxicity neutralization
assay [16]. Briefly, CHO-K1 cells in the exponential growth
stage were harvested and digested with 0.25% trypsin,
then inoculated to sterile, dry coverslips pre-treated
with anti-degreasing agent (poly-L-lysine) in a 6-well
plate (~105 cells/well). The overnight cultures were ran-
domly divided into 4 groups for treatment with no-TcdA
(normal control), TcdA (Calbiochem, Germany), TcdA fol-
lowing anti-TcdA serum pre-incubation, and TcdA with
anti-TcdA serum treatment. Except for the control group,
to the other 3 groups was added 100 μl of TcdA in PBS
(2 μg/ml). To the anti-TcdA serum pre-incubation group,
TcdA was added after 30 min pre-incubation with 100 μl of
0.22 μm-filtered serum; and to the anti-TcdA serum treat-
ment group, TcdA was added simultaneously with 100 μl
of 0.22 μm-filtered serum. The reaction in all treatments
was terminated after 12-hrs incubation. The coverslips
were washed 4 times with Hank’s buffered salt solution
and fixed with freshly made fixative (methanol-glacial
acetic acid, 3:1, v/v) for 5 min, followed by air-drying
and 15 min Giemsa stain. The stained coverslips were
air-dried, embedded with resin, and then examined under
a light microscope. Samples with 50% or more cell
rounding were considered positive if the cytotoxicity
was neutralized by TcdA antitoxin [16].
Flow cytometry assay
To examine the effect of hamster serum from the
membrane-anchored plasmid group on TcdA-induced
intestinal epithelial cell apoptosis, T84 cells in the expo-
nential growth stage were harvested and prepared in 4
groups: [1] normal control, cells received no reagent; [2]
TcdA treatment, cells received 100 μl of TcdA (final conc.
200 ng/ml) followed by 100 μl of PBS 1-h later; [3]
anti-TcdA serum pre-incubation, cells received 100 μl of
anti-TcdA serum followed by 100 μl of TcdA (final conc.
200 ng/ml) 1-h later; and [4] anti-TcdA serum treatment,
cells received 100 μl of TcdA (final conc. 200 ng/ml)
followed by 100 μl of anti-TcdA serum 30-min later. After
1-h treatment, ~5 × 105 cells were harvested from each
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stained with Annexin V-FITC and propidium iodide (PI).
The FITC and PI signals from stained cells were detected
using flow cytometry. Intestinal epithelial cell apoptosis was
examined by analyzing the binding rate of Annexin V-FITC
and cells, and dead or dying cells were scored by PI signals.Polymerase chain reaction (PCR) assay
Total RNA was extracted from cecum tissue using
Trizol reagent (Invitrogen, CA, USA), and then reverse-
transcribed into cDNA using PCR techniques. The obtained
cDNA served as template for PCR assay of monocyte
chemoattractant protein-1 (MCP-1), intercellular adhesion
molecule-1 (ICAM-1), interleukin-6 (IL-6), antiproliferative
protein (APRO) and growth-regulated protein-1 (Gro-1)
expression in cecum tissue using specific primers (Table 3).
The 50 μl PCR reaction contained 1 μl of forward primer
(20 μm), 1 μl of reverse primer (20 μm), 2 μl of cDNA
template, 5 μl of 10x Pfu PCR buffer, 4 μl of dNTP mix
(10 mM each), 0.5 μl of Pfu (5 U/μl), and double-distilled
H2O to make up the volume. PCR amplification was
done on a thermal cycler (Biometra UNO II, Göttingen,
German) by 30 cycles of denaturation at 94°C for 45 sec,
annealing at 58°C for 45 sec, and extension at 72°C for
45 sec, followed by a final extension step at 72°C for 10 min.
PCR products were electrophoresed on 2% agarose gel,
post-stained with Goldview DNA stain (Geneshun Biotech
Ltd, Guangzhou, China), and visualized using a gel imaging
system (Vilber Lourmat, France). Gel images were taken
using a CCD digital camera. The integral optical density
of DNA bands was calculated from the area and the
intensity of corresponding electrophoretic bands using
Gel-Pro Analyzer 4.0 software (Media Cybernetics, USA).
The mRNA expression levels of target genes were calcu-
lated from the optical density of the sample relative to
that of APRO (internal control).Table 3 Primers designed for targeting the mucosal inflamma
Gene Accession no. 5′ to
Gro-1 NM_008176 S: GC
AS: T
APRO X15267 S: GG
AS: C
ICAM-1 NM_010493 S: GG
AS: C
IL-6 NM_031268 S: TT
AS: G
MCP-1 NM_012333 S: CC
AS: C
S and AS denote the sense and antisense primers, respectively.Results
General symptoms of C. difficile-infected hamsters
In the control group, all hamsters had light stool, wet
perianal area and tail, less activity with response to stimuli,
and a soft abdomen on day 1 after the C. difficile chal-
lenge; few animals had bloody stools as observed by naked
eye. The majority of animals in the control group had
damp claws and lower abdomen, curved or arched bodies
with no activity, soft abdomen, disappeared balance, and
shrugged fur on day 2 post-challenge; few animals died.
All animals in the control group died by the end of day 4
post-challenge (Figure 2A). In the empty plasmid group,
animals subject to C. difficile challenge all had light stool
and a wet perianal area and tail on day 1 post-challenge;
some animals were less active but responded to stimuli;
one animal died on day 2 post-challenge (Figure 2A). After
L. lactis carrying the empty vector was administered again,
diarrhea symptoms were alleviated in the infected animals.
Till the end of the experiment, two animals still had diar-
rhea, but their perianal area and tail were not wet. In the
secreted-protein plasmid group, two of the animals sub-
ject to C. difficile challenge had diarrhea on day 1, but
their perianal area and tail were not wet. After recombi-
nant L. lactis carrying the secreted-protein plasmid was
administered again, diarrhea symptoms disappeared in
the animals by day 4 post-challenge. In the membrane-
anchored group, animals had no symptoms of diarrhea
(Table 4).Pathological changes in C. difficile-infected hamsters
Macropathological observations
After the C. difficile challenge, all animals in the control
group had cecal expansion and intestinal bleeding on
day 2 (Figures 3A and B). Extensive hemorrhagic lesions
were observed in the intestine (Figures 4A and B), some
of which occurred as mucosal defects. The worst lesionstory cytokine-encoding genes in hamster model











Figure 2 Effect of recombinant L. lactis vaccine after clostridium difficile challenge. (A) Cumulative mortalities caused by clindamycin-induced
Clostridium difficile-associated diseases (CDAD) in different groups of hamsters; (B) Mortalities caused by clindamycin-induced CDAD in different groups
of hamsters; (C) Survival rate (%) in different groups of hamsters; (D) Cumulative morbidities of diarrhea caused by clindamycin-induced CDAD in
different groups of hamsters; and (E) Comparison of body weight in different groups of hamsters before and after challenge with Clostridium difficile.
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dilation was detected in the small intestine, which was
thicker than the colon. The rectum had slight lesions,
with no feces observed in the colon. In the empty plasmid
group, one animal died on day 2 post-challenge, with a
slightly dilated cecum and intestinal mucosa hyperemia
(Figure 3C). In its intestinal cavity, a few hemorrhages
and obvious congestion and edema were observed within
the intestinal mucosa. Interspersed erosion was visible
(Figure 4C). Other animals of the empty plasmid groupsacrificed at the end of the experiment had a non-dilated
cecum and uncongested intestinal mucosa. Animals of the
secreted-protein and membrane-anchored plasmid groups
had a non-dilated intestine and formed feces in the colon
and rectum (Figures 3D and E), with no congestion or
edema in the intestinal mucosa (Figures 4D and E).
Histopathological observations
After the C. difficile challenge, animals in the control
group had mucosal defects, gland destruction, extensive
Table 4 Appearance of hamster in different groups after Clostridium difficile challenge (n = 8 each)




Diarrhea All on day 1 All on day 1 2 on day 1 No
Perianal and tail damp Yes Yes No No
Paw and abdomen damp Six on day 2 Only one on day 2 No No
Activity Decreased Decreased Normal Normal
Response to stimulation Decreased, even disappeared Only one weakened Normal Normal
Fur luster Lackluster Normal Normal Normal
Eating Decreased Almost normal Normal Normal
Death All One No No
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infiltration on day 2 (Figures 5A and B). By comparison,
animals in the empty plasmid group had less severe
mucosal defect, with a small amount of bleeding and
extensive neutrophil infiltration in the submucosa. More-
over, abscess formation was observed (Figures 5C and D).
In the secreted-protein plasmid group, animals showed
mild damage on the mucosal epithelia post-challenge, with
many neutrophils infiltrating the submucosa (Figure 5E).
In the membrane-anchored group, the animals had slight
defects in mucosa post-challenge, with a few neutrophils
infiltrating the submucosa (Figure 5F). Regarding the
macropathological and histopathological scores, there
are statistically significant differences between the con-
trol group and other plasmid treatment groups of ham-
ster (P < 0.005, Figure 6).
Statistical analysis of evaluation indices
Compared with the control group, the 3 immunization
groups had significantly lower mortality rate (P < 0.001,
Figure 2B) and higher survival rate/time (P < 0.001,
Figure 2C). Of the 3 immunization groups, secreted-
protein and membrane-anchored plasmid groups had
obviously lower mortality rate than the empty plasmid
group (Figure 2B). The incidence of diarrhea was sig-
nificantly different among all groups (P < 0.001), with
the highest level observed in control and empty plasmid
groups and the lowest level in the membrane-anchored
plasmid group (Figure 2D). As for the weight change from
before to after C. difficile challenge, the 3 immunizationFigure 3 Changes of intestine loop in all groups at the end of experim
formed stool in the control group; (C) Slightly dilated cecum in the empty
formed stool; and (D) Cecum of the secreted-protein and membrane-anch
bleeding, or dilation (E).groups had significantly lower values than the control,
whereas the secreted-protein and membrane-anchored
plasmid groups had significantly lower values than the
empty plasmid group (P < 0.001, Figure 2E). There was
no significant difference in weight change values between
the secreted-protein and membrane-anchored plasmid
groups (P > 0.05).
Occurrence and abundances of C. difficile and L. lactis in
hamster specimens
Prior to the challenge experiment, C. difficile was not
detected in any feces samples by laboratory cultivation
and isolation. However, C. difficile was detected in diarrhea
stools and intestinal tissues of all animals in the control
group after the C. difficile challenge. In the empty plasmid
group, C. difficile was detected in diarrhea stools from all
animals 1 day post-challenge, as well as intestinal tissue
homogenate of the dead animal 2 days post-challenge. Till
the end of the experiment, C. difficile was obtained from
3 animals’ stools in the empty plasmid group. In the
secreted-protein plasmid group, C. difficile was obtained
from the stools of two animals, but not in any intestinal
tissue specimens. In the membrane-anchored plasmid
group, C. difficile was detected in the stools of one
animal only, but not in its intestinal tissues.
After 1-week administration of CLDM, lactic acid bac-
teria or bifidobacteria were not isolated from any groups
of hamster while fungi were detected in stool samples,
suggesting grade III dysbacteriosis (Table 5). To enhance
the immunization, L. lactis was administered again 2 daysent. (A&B) Enlarged and bleeding cecum and upper colon without
plasmid group, with high tension, hydropsia, congestion and no
ored plasmid groups, with formed stool and no sign of congestion,
Figure 4 Macropathological observations in all groups. (A&B) Defective cecal mucosa in the control group, with bleeding, edema and
disappearing of vascular lakes. Colon mucosa adjacent to the cecum with edema and ulcer; (C) Cecal mucosa of the empty plasmid group, with
edema, scattered bleeding points and erosion; (D) Cecal mucosa of the secreted-protein plasmid group; and (E) Cecal mucosa of the
membrane-anchored plasmid group.
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http://www.biomedcentral.com/1471-230X/13/117after the C. difficile challenge. As a result, L. lactis was iso-
lated from stools of animals in the 3 immunization groups
on day 3 post-challenge. The number of L. lactis on day
14 was less than that that detected on day 7 post-
challenge. In addition, L. lactis was isolated from intestinal
mucosa homogenates of the 3 immunization groups, while
C. difficile was detected in intestinal mucosa homogenates
of animals in the empty plasmid group (Table 5).
Anti-TcdA antibody tilter in hamster serum and
intestinal fluid
ELISA assay showed that anti-TcdA IgG and IgA antibodies
were produced in serum and intestinal fluid specimens ofFigure 5 Histopathological observations in all groups. (A&B) Section
of cecal mucosa in the control group. (C&D) Section of cecal mucosa
in the empty plasmid group. (E) Section of cecal mucosa in the
secreted-protein plasmid group. (F) Section of cecal mucosa in the
membrane-anchored plasmid group.all animals. In membrane-anchored plasmid group, the
titers of IgG and IgA antibodies directed against TcdA
were 1.5 × 104 and 6.7 × 102 in the serum, and 1.45 × 104
and 1 × 102 in the intestinal fluid, respectively. In secreted-
protein plasmid group, the titers of anti-TcdA IgG and IgA
were 9.5 × 103 and 5.6 × 102 in the serum, and 9.4 × 103 and
7.5 × 101 in intestinal fluid, respectively. In the empty
plasmid group, the titers of anti-TcdA IgG and IgA were
2.4 × 103 and 3.6 × 102 in the serum, and 3.5 × 103 and
7.5 × 101 in intestinal fluid, respectively. In the control
group, the titers of anti-TcdA IgG and IgA were 6 × 102
and 2 × 102 in the serum, and 7.3 × 102 and 6.3 × 101 in
intestinal fluid, respectively. Overall, the anti-TcdA IgG
titers of hamster serum and intestinal fluid were signifi-
cantly higher in the secreted-protein and membrane-
anchored plasmid groups than in the empty plasmid
and control groups (P < 0.001), whereas the anti-TcdA
IgA titer of serum was significantly higher in the secreted-
protein and membrane-anchored plasmid groups than in
the control group (P < 0.05). The anti-TcdA IgA titer of
intestinal fluid had no significant differences among all
groups (Figure 7).
Cell morphology as influenced by toxin neutralization
Light microscopy showed that in the control group, cells
were uniform in size and spindle-shaped. In the prolifer-
ative phase, cells were round-shaped while the nucleus
appeared to be normal (Figure 8A). After TcdA treatment,
the cell shape changed from spindly to round while the
cell size varied along with nuclear condensation, frag-
mentation and dissolution (Figure 8B). In the serum pre-
incubation group, cells became slightly round with visible
spindles (Figure 8C). In the serum treatment group, some
cells turned round and narrow and showed nuclear conden-
sation, whereas some cells remained spindly (Figure 8D).
The effect of anti-TcdA serum on TcdA-induced intestinal
epithelial cell apoptosis
Flow cytometry showed that a large number of intestinal
epithelial cells died after TcdA treatment, with dead and
apoptotic cells accounting for 41.59% and 18.34% of the
total cells, respectively. By comparison, the proportions
of dead and apoptotic cells in total cells were obviously
smaller in the other 3 groups, i.e., 7.39%, and 6.47% in
Figure 6 Comparison of macropathological and histopathological scores among different groups of hamsters. The macropathological
and histopathological scores are higher in the control group than in the 3 immunization groups.
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http://www.biomedcentral.com/1471-230X/13/117the anti-TcdA serum pre-incubation group, 12% and 8.78%
in the anti-TcdA serum treatment group, and 3.9% and
3.87% in the control group, respectively. Of these, the pro-
portions of dead and apoptotic cells in total cells were sig-
nificantly smaller in the anti-TcdA serum pre-incubation
group than in the TcdA treatment (χ2 = 83.511, P < 0.001)
and anti-TcdA serum treatment groups (χ2=6.125, P < 0.05)
(Figure 9).
Expression of mucosal inflammatory cytokines in hamster
PCR assay showed that the mRNA expression levels of
mucosal inflammatory cytokines, i.e., ICAM-1, MCP-1,
IL-6, and Gro-1 were generally higher in the control and
empty plasmid groups than in secreted-protein and
membrane-anchored plasmid groups (Figure 10). ICAM-1
and MCP-1 mRNA expression levels varied in similar
trends and large ranges, whereas Gro-1 mRNA expression
levels hadminor changes among the 4 groups. Overall,
the secreted-protein plasmid group had higher ICAM-1,
MCP-1, IL-6, and Gro-1 mRNA expression levels than
the membrane-anchored group.
Discussion
Development of recombinant L. lactis live vaccine for
C. difficile
In accordance with the work by Dieye et al. [7], we previ-
ously constructed an exogenous gene expression system
in L. lactis [12], and successfully expressed 14CDTA inTable 5 Cultivation and enumeration of Lactococcus lactis in cec
Group (n = 8 each) L. lactis in cecal mu
(104CFU/g)
Control group 0.413 ± 0.1
Empty plasmid group 104.75 ± 8.41 ab
Secreted-protein plasmid group 108.25 ± 4.57 ab
Membrane-anchored plasmid group 105 ± 3.9 ab
a compared with control group (F=96.289, P=0.000); b compared among immuniza
(F=0.690, P=0.513); d compared among immunization groups (F=1.9, P=0.174); and
appearance of opportunistic flora on top of hemolytic and lactose-negative escheri
(Ladodo scale).the recombinant L. lactis [13]. In the present study, we
re-constructed the gene expression system by PCR-based
gene assembly of the P59 promoter, SPUsp45, 14CDTA
containing 12 restriction sites, and the nontoxic adjuvanted
TETC, and further developed the recombinant L. lactis live
vaccine, a live ecological preparation for oral immunization
of CDI. As compared to that designed by Dieye et al. [7],
our modified expression system is more advantageous
because it contains an increased number of cloning sites,
which are commonly used in gene cloning. Therefore, the
modified expression system can be applicable for a variety
of bio-engineering purposes. In addition, its immunization
effect on CDI animal model is potentially enhanced
because of the adjuvant activity of TETC.
Establishment of CDI animal model in golden hamster
In order to validate the effect of the recombinant
L. lactis live vaccine for preventing CDI, we established
a CDI animal model in golden hamster using CLDM as
the inducer. According to Torres et al. [3] and Larson
et al. [17], CLDM is superior to ampicillin, penicillin,
and cefuroxime for inducing CDIs in animal models
(74 days of susceptible period). In our preliminary experi-
ments, administration of 105CFU C. difficile to hamsters
after 1-week gavage or intramuscular injection of ceftazi-
dime failed to induce the CDI-associated diarrhea, whereas
C. difficile challenge after 2-day administration of CLDM
resulted in diarrhea symptoms in the animals (data notal mucosa and stool of Clostridium difficile-infected hamsters
cosa L. lactis from stool (106CFU/g)
Day 7 Day 14
Fungi*
109 ± 6.95 e 69.38 ± 6.44dc
124.63 ± 7.92 e 64.38 ± 6.37dc
104 ± 3.45 e 53.75 ± 4.30dc
tion groups (F=0.107, P=0.899); e compared among immunization groups
c compared between days 7 and 14, P < 0.01. * Grade III dysbacteriosis –
chia, growth of cocci and suppression of lacto- and bifidobacteria
Figure 7 Anti-toxin A (TcdA) IgG and IgA antibodies in serum and intestinal fluid of different groups of hamsters. The anti-TcdA IgA titer
in serum of secreted-protein and membrane-anchored plasmid groups was higher than that of the control group (P < 0.05). There was no
significant difference in anti-TcdA IgA titer of intestinal fluid among all groups.
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http://www.biomedcentral.com/1471-230X/13/117shown). In addition, we tested SD rats and BALB/c mice as
CDI animal models, but neither showed CDI-associated
diarrhea symptoms after 1-week administration of CLDM
or C. difficile (data not shown).
As the live vaccine carried by recombinant L. lactis might
serve as a probiotic preparation, we performed C. difficile
challenge on the animals after their intestinal flora were dis-
turbed by 1-week administration of CLDM. Because no L.
lactis was isolated from animals thereafter, we assume that
this procedure could avoid the potential effect of recombin-
ant L. lactis live vaccine as a probiotic preparation while
simulating clinical infection of C. difficile in practice. That
is, long-term use of antibiotics causes the disturbance of
intestinal flora, negatively affecting the inhibitory factors
of C. difficile colonization, thereby leading to CDIs. After
the C. difficile challenge, all animals in the control group
suffered severe diarrhea (Table 4), indicating that the
CDI model was successfully established in the hamsters.Figure 8 Results of cytotoxicity neutralization assay. (A) Control:
nucleus was normal. (B) Clostridium difficile toxin A (TcdA) treatment:
condensation, fragmentation and dissolution of nuclei were found.
(C) Anti-TcdA serum pre-treatment: cells became slightly round but
still spindly. (D) Anti-TcdA serum treatment: cells became round and
narrow; nuclei appeared condensed, but some cells were still spindly
(×200 magnification).Effect of recombinant L. lactis live vaccine on
C. difficile-infected animal model
To evaluate the protective effect of recombinant L. lactis
live vaccine on C. difficile-infected animals, we used the
empty shuttle vector carried by L. lactis as negative con-
trol. After the C. difficile challenge, all animals of the
empty plasmid group had diarrhea on day 1 (Table 4),
suggesting that the intestinal flora were disturbed by
continuous administration of CLDM. Compared to the
blank control, empty plasmid group had lighter diarrhea
symptoms. Despite one died after the C. difficile challenge,
the diarrhea symptoms were alleviated in the remaining
animals, and a few became normal after re-administration
of L. lactis carrying the empty plasmid. Together these
observations indicate that the probiotic L. lactis has a
protective effect on CDI animal model and may prevent
C. difficile-associated diarrhea in animals by inhibiting
C. difficile colonization and/or other mechanisms [18,19].
In the animal group treated with recombinant L. lactis
carrying secreted-protein plasmid, diarrhea symptoms
were found significantly lighter than those in the control
and empty plasmid groups (Table 4). Immunological
evaluation by ELISA assay showed that the IgG antibody
produced in serum and intestinal fluid of secreted-
protein and membrane-anchored plasmid groups reacted
with TcdA while IgA showed no obvious effect (Figure 7).
These observations can be related to previous work by
Vaerman et al. [20], which indicates that the IgG antibody
in serum and intestinal fluid plays a significant role in
protecting human and experimental animals from CDI,
and that IgA plays aminor role in prevention and control
of CDIs. In the present study, none of the animals died in
secreted-protein plasmid group after the C. difficile chal-
lenge. In fact, their diarrhea symptoms were relatively
light (Table 4). This is because TcdA acts an enterotoxin
as well as a cytotoxin, with a lower cytotoxicity than the
C. difficile toxin B [19]. Thus, application of TcdA mainly
causes intestinal cavity hemorrhage and effusion while
preventing the infected animals from death.
Figure 9 Effect of anti-Clostridium difficile toxin A (TcdA) sera against the cytotoxicity of TcdA assayed by flow cytometry. (A) Control;
(B) TcdA treatment; (C) Anti-TcdA serum pre-treatment; and (D) Anti-TcdA serum treatment.
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http://www.biomedcentral.com/1471-230X/13/117In the group vaccinated with recombinant L. lactis car-
rying the membrane-anchored plasmid, no animals had
diarrhea symptoms throughout the experiment (Table 4).
Pathological analysis and flow cytometry assay confirmed
that oral immunization with the recombinant L. lactis
carrying membrane-anchored plasmid most effectively
prevented C. difficile-induced diarrhea in the animal model
as well as apoptosis in the intestinal epithelial cells
(Figures 3, 4, 5, and 9). Compared to other immunization
groups, membrane-anchored plasmid group had higher
tilter of anti-TcdA IgG antibody in the serum and intes-
tinal fluid (Figure 7), with downregulated expression
of mucosal inflammatory cytokines, especially IL-6Figure 10 Relative values of the grayscale mRNA levels of mucosal in(Figure 10). It was possible that the number of exogenous
L. lactis cells in vivo gradually decreased due to phagocytosis
by the M cells on the intestinal wall. Because membrane-
anchored plasmid anchors the recombinant protein onto
the cell wall, phagocytosis of L. lactis cells carrying such
plasmid can more efficiently deliver the antigen to the
immune system than that of secreted-protein plasmid.
Consequently, the recombinant L. lactis carrying membrane-
anchored plasmid is most effective for preventing CDI
compared to other immunization treatments. Further in-
vestigation is guaranteed to explore molecular mechanism
(s) of CDI prevention by the recombinant L. lactis live
vaccine.flammatory cytokines in different groups of hamsters.
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http://www.biomedcentral.com/1471-230X/13/117Conclusion
In this study, we constructed a live Lactococcus lactis
vaccine expressing the TETC and 14CDTA, then we proved
the effectiveness of the vaccine in a hamster modle. We also
found that the recombinant L. lactis carrying membrane-
anchored plasmid is more effective for preventing CDI than
the recombinant L. lactis carrying the secreted-protein plas-
mid. Further studies are needed to elucidate the mecha-
nisms of the vaccine for preventing CDI. There is a long
way to go for the vaccine using by the human owing to
the plasmid containing erythromycin resistant gene.
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